2026-06-14T05:06:55Zhttps://repisalud.isciii.es/rest/oai/requestoai:repisalud.isciii.es:20.500.12105/129372025-05-23T13:14:19Zcom_20.500.12105_2052com_20.500.12105_2051col_20.500.12105_19609
Repisalud
author
McConnell, Michael J
author
Martin-Galiano, Antonio Javier
funder
Instituto de Salud Carlos III
2021-05-12T09:14:22Z
2021-05-12T09:14:22Z
2021
Front Immunol. 2021 Apr 16;12:666742.
10.3389/fimmu.2021.666742
1664-3224
Frontiers in Immunology
33936107
http://hdl.handle.net/20.500.12105/12937
Vaccines and monoclonal antibodies are promising approaches for preventing and treating infections caused by multidrug resistant Acinetobacter baumannii. However, only partial protection has been achieved with many previously tested protein antigens, which suggests that vaccines incorporating multiple antigens may be necessary in order to obtain high levels of protection. Several aspects that use the wealth of omic data available for A. baumannii have not been fully exploited for antigen identification. In this study, the use of fractionated proteomic and computational data from ~4,200 genomes increased the number of proteins potentially accessible to the humoral response to 8,824 non-redundant proteins in the A. baumannii panproteome. Among them, 59% carried predicted B-cell epitopes and T-cell epitopes recognized by two or more alleles of the HLA class II DP supertype. Potential cross-reactivity with human proteins was detected for 8.9% of antigens at the protein level and 2.7% at the B-cell epitope level. Individual antigens were associated with different infection types by genomic, transcriptomic or functional analyses. High intra-clonal genome density permitted the identification of international clone II as a "vaccitype", in which 20% of identified antigens were specific to this clone. Network-based centrality measurements were used to identify multiple immunologic nodes. Data were formatted, unified and stored in a data warehouse database, which was subsequently used to identify synergistic antigen combinations for different vaccination strategies. This study supports the idea that integration of multi-omic data and fundamental knowledge of the pathobiology of drug-resistant bacteria can facilitate the development of effective multi-antigen vaccines against these challenging infections.
eng
Antibiotic resistance
Epitope
Multidrug resistance
Reverse vaccinology
Systems biology
Designing Multi-Antigen Vaccines Against Acinetobacter baumannii Using Systemic Approaches
research article
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
URL
https://repisalud.isciii.es/bitstreams/283db9a6-a253-4ceb-926d-121b8eb29348/download
File
MD5
8646f2be9a8a68efaf7a552fa64d07f3
8182396
application/pdf
DesigningMultiAntigenVaccines_2021.pdf
URL
https://repisalud.isciii.es/bitstreams/a1b0a689-f797-4085-a494-9218172ea5aa/download
File
MD5
cfd0799b97d7469c9989b4e634600e03
180076
application/pdf
DesigningMultiAntigenVaccinesSupplementaryMaterialImage_1_2021.pdf
URL
https://repisalud.isciii.es/bitstreams/da82a009-005e-480b-aace-25cae9816ab6/download
File
MD5
60f174d58d54170ec79dc96d8df84925
200970
application/pdf
DesigningMultiAntigenVaccinesSupplementaryMaterialImage_2_2021.pdf
URL
https://repisalud.isciii.es/bitstreams/1391955d-401b-4fbd-a2d0-7220c2858dcf/download
File
MD5
5a632b27bc9d8b724baeead01ae999a9
104364
application/pdf
DesigningMultiAntigenVaccinesSupplementaryMaterial_Table_1_2021.pdf
URL
https://repisalud.isciii.es/bitstreams/5558bcd6-f89a-424c-81ac-c58af14eb6e1/download
File
MD5
143cb9584dba3e1a228f3918655ea277
12213
application/pdf
DesigningMultiAntigenVaccinesSupplementaryMaterial_Table_2_2021.pdf
URL
https://repisalud.isciii.es/bitstreams/2c74e187-a252-45ac-a766-a4ee9ae3a2b4/download
File
MD5
ba67e74abad5be9ee804458e89fbd01b
177033
application/pdf
DesigningMultiAntigenVaccinesSupplementaryMaterial_Table_3_2021.pdf
URL
https://repisalud.isciii.es/bitstreams/45fa5e77-0604-4d2f-af9a-40a0fcf8f420/download
File
MD5
c3757a205617849e596242d89f1d26ee
271659
application/pdf
DesigningMultiAntigenVaccinesSupplementaryMaterial_Table_4_2021.pdf
URL
https://repisalud.isciii.es/bitstreams/b687bbb2-bafb-4b78-b06d-4947e619742b/download
File
MD5
28709d2f078907f32e8adaa27d6eef07
11525
application/pdf
DesigningMultiAntigenVaccinesSupplementaryMaterial_Table_5_2021.pdf
URL
https://repisalud.isciii.es/bitstreams/5a9d2a91-c567-4f4b-a93d-c106f48be439/download
File
MD5
78c898e1e6ea177bd398711f83c339d1
104213
application/pdf
DesigningMultiAntigenVaccinesSupplementaryMaterial_Table_6_2021.pdf
URL
https://repisalud.isciii.es/bitstreams/b1d9773f-4817-430f-8194-a991eae7ea38/download
File
MD5
221e2956aa61a5b1d76d552fba318dcb
17173
application/pdf
DesigningMultiAntigenVaccinesSupplementaryMaterial_Table_7_2021.pdf
URL
https://repisalud.isciii.es/bitstreams/e89ee783-5442-4591-b1b2-fd541b2e21f4/download
File
MD5
9d513c7ce39681beed91ad8e895448d6
109457
application/pdf
DesigningMultiAntigenVaccinesSupplementaryMaterial_Table_8_2021.pdf
URL
https://repisalud.isciii.es/bitstreams/64199223-3f02-4315-b090-8ab39ac48e37/download
File
MD5
c15ab571c9aac7b30b804020e4ae9c09
61081
text/plain
DesigningMultiAntigenVaccines_2021.pdf.txt
URL
https://repisalud.isciii.es/bitstreams/f5d2b20f-de24-4094-b4cd-222ae2eff3b1/download
File
MD5
399af7ecdc4cfb7f176ad636c2dc465d
803
text/plain
DesigningMultiAntigenVaccinesSupplementaryMaterialImage_1_2021.pdf.txt
URL
https://repisalud.isciii.es/bitstreams/4d39e309-7bec-4439-ac6a-fecfca09a56e/download
File
MD5
e617d0f6e8d5041292c2a1a898a0d376
321
text/plain
DesigningMultiAntigenVaccinesSupplementaryMaterialImage_2_2021.pdf.txt
URL
https://repisalud.isciii.es/bitstreams/279b6ff4-0f90-4e65-ac5b-5fa38607a8da/download
File
MD5
8c232f16870d0b216c38fb9dc9829904
2884
text/plain
DesigningMultiAntigenVaccinesSupplementaryMaterial_Table_1_2021.pdf.txt
URL
https://repisalud.isciii.es/bitstreams/8214b652-56da-4d12-87b3-0b19e2419f63/download
File
MD5
f53848bdba1c31dbbb04fa692feaea8d
1144
text/plain
DesigningMultiAntigenVaccinesSupplementaryMaterial_Table_2_2021.pdf.txt
URL
https://repisalud.isciii.es/bitstreams/306c33ed-e04e-4f48-b51e-8a2017a1aac6/download
File
MD5
b64ca03ab0158de4a7cec2e605d637d1
1171
text/plain
DesigningMultiAntigenVaccinesSupplementaryMaterial_Table_3_2021.pdf.txt
URL
https://repisalud.isciii.es/bitstreams/83bca5f5-8323-4f00-bab7-6034521d1ba0/download
File
MD5
a801dbf004d3e596271327a204e0840c
2156
text/plain
DesigningMultiAntigenVaccinesSupplementaryMaterial_Table_4_2021.pdf.txt
URL
https://repisalud.isciii.es/bitstreams/b20def8a-5661-4805-bd0e-51181175e617/download
File
MD5
eeabdbecb50f3d2d240b7e1856a64f96
580
text/plain
DesigningMultiAntigenVaccinesSupplementaryMaterial_Table_5_2021.pdf.txt
URL
https://repisalud.isciii.es/bitstreams/390f580a-e5e0-4a6d-adef-673516d8e4be/download
File
MD5
9f6e6f2240b9b85bfd813c059b836aed
1833
text/plain
DesigningMultiAntigenVaccinesSupplementaryMaterial_Table_6_2021.pdf.txt
URL
https://repisalud.isciii.es/bitstreams/6b7484c1-61dc-40d6-ae52-58f088cb2a3f/download
File
MD5
7321f1ecd8f25e64752b8f64fbf40e6d
1450
text/plain
DesigningMultiAntigenVaccinesSupplementaryMaterial_Table_7_2021.pdf.txt
URL
https://repisalud.isciii.es/bitstreams/d7fb7066-7639-4d2b-98c5-b1a3af4cec58/download
File
MD5
50c85a74e59eb8f076a7eafa783674f4
2392
text/plain
DesigningMultiAntigenVaccinesSupplementaryMaterial_Table_8_2021.pdf.txt